Stocklytics Platform
bioAffinity Technologies, Inc.
BIAF44
$0.47arrow_drop_down11.12%-$0.06
NASDAQ - As of Apr 14, 1:03 PM EDT Market Open
Penny Stock
BIAF44

$0.47

arrow_drop_down11.12%

Performance History

arrow_drop_down82.64%

(-$2.28 )

Stocklytics logo
Key Stats
Open$0.53
Prev. Close$0.54
EPS-0.91
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$8.56M
PE Ratio-
LOWHIGH
Day Range0.47
0.54
52 Week Range0.24
3.62
Ratios
P/B Ratio2.30
Revenue$2.53M
Operating M. %-87.08%
Earnings$0.00
Earnings Growth %2.66%
EBITDA Margin %-317.26%
ROE %-151.52%
EPS-0.91

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Eli Lilly & Co
LLY84
Price$747.24
Perf. (24h)arrow_drop_up2.06%$15.16
Market Cap$669.13B
UnitedHealth Group
UNH69
Price$579.87
Perf. (24h)arrow_drop_down3.05%-$18.29
Market Cap$540.14B
Johnson & Johnson
JNJ61
Price$153.18
Perf. (24h)arrow_drop_up1.09%$1.65
Market Cap$397.30B
AbbVie
ABBV67
Price$178.15
Perf. (24h)arrow_drop_up1.99%$3.50
Market Cap$316.01B

About bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies, Inc. (BIAF) is a biotechnology company that focuses on the development and commercialization of diagnostic tests for early cancer detection. The company's flagship product, CyPath® Lung, is a non-invasive blood test that can detect multiple types of cancers, including lung cancer, at their earliest stages. This test offers a higher sensitivity and specificity compared to traditional screening methods, such as CT scans or X-rays. With the potential to revolutionize cancer detection, bioAffinity Technologies is poised for significant growth in the medical diagnostics industry.
One of the key advantages of bioAffinity Technologies' CyPath® Lung test is its ability to detect lung cancer in its early stages when treatment options are more effective and chances of survival are higher. This can potentially lead to improved patient outcomes and reduced healthcare costs. The company's proprietary technology is based on the binding properties of a fluorescent dye to cancerous cells, allowing for the detection and identification of cancer biomarkers. This innovative approach has the potential to transform the current landscape of cancer diagnosis and treatment.
Show more
Websitecall_made
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Ms. Maria Zannes J.D.
Headquarters
San Antonio
Employees
14
Exchange
NASDAQ
add bioAffinity Technologies, Inc. to watchlist

Keep an eye on bioAffinity Technologies, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is bioAffinity Technologies, Inc. 's (BIAF) price per share?

The current price per share for bioAffinity Technologies, Inc. (BIAF) is $0.48. The stock has seen a price change of -$0.06 recently, indicating a -11.13% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for bioAffinity Technologies, Inc. (BIAF)?

For bioAffinity Technologies, Inc. (BIAF), the 52-week high is $3.62, which is 655.74% from the current price. The 52-week low is $0.24, the current price is 97.93% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is bioAffinity Technologies, Inc. (BIAF) a growth stock?

bioAffinity Technologies, Inc. (BIAF) has shown an average price growth of -1.65% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying bioAffinity Technologies, Inc. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is bioAffinity Technologies, Inc. (BIAF) stock price performance year to date (YTD)?

As of the latest data, bioAffinity Technologies, Inc. (BIAF) has a year-to-date price change of -47.36%. Over the past month, the stock has experienced a price change of 35.16%. Over the last three months, the change has been -36.53%. Over the past six months, the figure is -74.39%.
help

Is bioAffinity Technologies, Inc. (BIAF) a profitable company?

bioAffinity Technologies, Inc. (BIAF) has a net income of -$7.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 31.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -87.08% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.53M, although specific revenue growth data is currently not available. The gross profit is $791.62K. Operating income is noted at -$7.97M. Furthermore, the EBITDA is -$7.62M.
help

What is the market capitalization of bioAffinity Technologies, Inc. (BIAF)?

bioAffinity Technologies, Inc. (BIAF) has a market capitalization of $8.56M. The average daily trading volume is 0.49, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level